News

Selection News

2025.08.18
Analyst Report[Full report] (Shared Research)
2025.08.12
2025年12月期中間決算説明会の動画を掲載しました。(Japanese only)
2025.08.12
SymBio Announces Abstract on Brincidofovir for the Treatment of Malignant Brain Tumors (Glioblastoma) Accepted for Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting to be Held in November 2025
2025.08.05
中間決算説明会資料(2025年12月期)(Japanese only)
2025.07.28
SymBio to Present Preclinical Data on Brincidofovir in Head and Neck Cancer at ESMO 2025 Congress
2025.06.30
SymBio Submits Clinical Trial Application for a Phase 3 Global Study Evaluating IV Brincidofovir for the Treatment of Adenovirus Infection after HSCT
2024.07.12
SymBio Pharmaceuticals Announces Publication of Research Showing Antiviral Drug Brincidofovir Inhibits Infectious Viral Production of Polyomavirus
2023.11.17
Notice of Relocation of Head Office
2023.11.06
SymBio To Present Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
2023.10.12
The Results of CRADA Study on Brincidofovir in Multiple Sclerosis Presented at the 9th Joint ECTRIMS-ACTRIMS Meeting
2023.07.20
Notice of Personnel Changes at SymBio Pharma USA, Inc.
2023.06.12
Presentation of the Results of Biomarker Research Predicting the Antitumor Effects of Brincidofovir at the 17th ICML
2023.05.29
IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial
2023.04.24
SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease
2023.03.22
Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)